Skip to Main Content

Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with the salted caramel mocha for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Eli Lilly (LLY) employees accused an executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing its Covid-19 treatment, Reuters reports. The unsigned report, filed April 8 in Lilly’s confidential employee complaint system, asserts the executive at the Branchburg, N.J., plant rewrote findings by Lilly technical experts to make conclusions appear more favorable to the company. The plant has been under investigation by the Food and Drug Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!